Comparison of baseline characteristics in the derivation and external validation sample
| Derivation sample (n=317) | External validation sample (n=264) | p Value | |
| Age (years) | 57±16 | 61±16 | 0.015 |
| Cancer | 21 (7%) | 36 (14%) | 0.005 |
| Previous endocarditis | 28 (9%) | 12 (4.5%) | 0.040 |
| Prosthetic | 114 (36%) | 57 (22%) | <0.001 |
| Illicit injection drug use | 16 (5%) | 9 (3%) | 0.333 |
| HIV | 10 (3%) | 8 (3%) | 0.931 |
| Clinical manifestations | |||
| Acute onset | 133 (43%) | 179 (68%) | <0.001 |
| Fever | 223 (70%) | 245 (93%) | <0.001 |
| Splenomegaly | 35 (11%) | 15 (6%) | 0.020 |
| Stroke | 30 (9.5%) | 52 (20%) | <0.001 |
| Haematuria | 135 (51%) | 72 (27%) | <0.001 |
| Radiographic findings | |||
| Cardiac enlargement | 177 (56%) | 108 (41%) | <0.001 |
| Septic emboli | 1 (0.3%) | 8 (3%) | 0.013 |
| Pulmonary congestion | 120 (38%) | 73 (28%) | 0.007 |
| Causative microorganism | |||
| Streptococcus viridans | 54 (17%) | 54 (20%) | 0.291 |
| Staphylococcus aureus | 53 (17%) | 57 (22%) | 0.136 |
| Coagulase-negative staphylococci | 48 (15%) | 24 (9%) | 0.028 |
| Enterococci | 25 (8%) | 37 (14%) | 0.017 |
| Polymicrobial | 16 (5%) | 4 (2%) | 0.020 |
| Negative cultures | 48 (15%) | 19 (7%) | 0.003 |
| Valve involved | |||
| Aortic native valve | 124 (34%) | 130 (44%) | 0.006 |
| Mitral prosthesis | 63 (17%) | 26 (9%) | 0.002 |
| Vegetations | 238 (79%) | 237 (91%) | <0.001 |
| Periannular complications | 90 (28%) | 56 (21%) | 0.047 |
| Fistula | 29 (10%) | 9 (3%) | 0.001 |
| Valve perforation | 28 (9%) | 41 (16%) | 0.030 |